Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-28
2007-08-28
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
10373196
ABSTRACT:
Compositions and methods for suppressing the immune system of a mammal using ubiquitin and derivatives and analogs thereof.
REFERENCES:
Ciecacute-Michalska et.al. Przeglad Lekarski, vol. 55, 5, 1998, p. 298-300.
www.gicare.com Jackson Gastroenterology, PSC (Primary Sclerosing Cholangitis.
Nabika et al., “Synergistic Effect Of Ubiquitin On Lipopolysaccharide-Induced TNF-Alpha Production in Murine Macrophage Cell Line RAW 264.7 Cell,” Biochimica et Biophysica Acta. 1999,vol. 1450, pp. 25-34.
Asseman et al., “A Radioimmunoassay for the Quantification of Human Ubiquitin in Biological Fluids: Application to Parasitic and Allergic Diseases,” Journal of Immunological Methods, 1994, vol. 173, pp. 93-101.
Majetschak et al., “Extracellular Ubiquitin Inhibits TNF-Alpha Response to Endotoxin in Peripheral Blood Mononuclear Cells and Regulates Endotoxin Hyporesponsiveness in Critical Illness,” Blood, Mar. 2003, vol. 101, No. 5, pp. 1882-1890.
Majetschak et al, “Therapeutic Potential of Exogeneous Ubiquitin During Resuscitation from Severe Trauma,” 2003, A.A.S.T. Webnet Domain.
Goldstein, Gideon et al., “Isolation of a Polypeptide . . . ”, Proc. Natl. Acad. Sci. USA, vol. 72 No. 1, pp. 11-15, Jan. 1975.
Szewczuk, Zbigniew et al., “Immunosuppressory Activity . . . ”, Biopolymers vol. 74, 352-362 (2004).
Earle, Steven et al., “Ubiquitin reduces fluid shifts . . . ”, Surgery, 2005, vol. 138:431-438.
Ciećko-Michalska, Irena et al., “Primary sclerosing cholangitis . . . ”, Med Sci Monit, 1997: 3(2): 238-241.
Zdzislaw, Zak et al., “Immunochemical and physicochemical prosperties . . . Part 1”, Dept of Animal Biochemistry, Institute of Molecular Biology, Materia Medica Poland, Fasc. 2 (39).
Zdzislaw, Zak et al., “Immunochemical and physicochemical properties . . . Part 2”, Dept of Animal Biochemistry, Institute of Molecular Biology, Materia Medica Poland, Fasc. 2 (39).
Manuscript: Majetschak, Matthias, “Brief Report: Prolongation of skin graft survival by exogenous ubiquitin”, pp. 1-16 with attached Figure.
Majetschak Matthias
Proctor Kenneth G.
Audet Maury
Hobbs Ann S.
Tsang Cecilia J.
University of Heidelberg
University of Miami
LandOfFree
Ubiquitin and ubiquitin related molecules for treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ubiquitin and ubiquitin related molecules for treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ubiquitin and ubiquitin related molecules for treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3890088